Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer
- PDF / 1,014,294 Bytes
- 11 Pages / 595.276 x 793.701 pts Page_size
- 92 Downloads / 191 Views
RESEARCH
Open Access
Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer Mónica Castro2, Laura Grau1, Patricia Puerta1, Liliana Gimenez2, Julio Venditti3, Silvia Quadrelli3, Marta Sánchez-Carbayo1*
Abstract Background: Changes in DNA methylation of crucial cancer genes including tumor suppressors can occur early in carcinogenesis, being potentially important early indicators of cancer. The objective of this study was to examine a multiplexed approach to assess the methylation of tumor suppressor genes as tumor stratification and clinical outcome prognostic biomarkers for lung cancer. Methods: A multicandidate probe panel interrogated DNA for aberrant methylation status in 18 tumor suppressor genes in lung cancer using a methylation-specific multiplex ligation-dependent probe amplification assay (MSMLPA). Lung cancer cell lines (n = 7), and primary lung tumors (n = 54) were examined using MS-MLPA. Results: Genes frequently methylated in lung cancer cell lines including SCGB3A1, ID4, CCND2 were found among the most commonly methylated in the lung tumors analyzed. HLTF, BNIP3, H2AFX, CACNA1G, TGIF, ID4 and CACNA1A were identified as novel tumor suppressor candidates methylated in lung tumors. The most frequently methylated genes in lung tumors were SCGB3A1 and DLC1 (both 50.0%). Methylation rates for ID4, DCL1, BNIP3, H2AFX, CACNA1G and TIMP3 were significantly different between squamous and adenocarcinomas. Methylation of RUNX3, SCGB3A1, SFRP4, and DLC1 was significantly associated with the extent of the disease when comparing localized versus metastatic tumors. Moreover, methylation of HTLF, SFRP5 and TIMP3 were significantly associated with overall survival. Conclusions: MS-MLPA can be used for classification of certain types of lung tumors and clinical outcome prediction. This latter is clinically relevant by offering an adjunct strategy for the clinical management of lung cancer patients.
Background Lung cancer is the third most frequent tumor, representing the leading cause of cancer death [1]. Non-small cell lung cancer (NSCLC) is the most common variant. NSCLC is the superseding term for various types of lung cancer such as the most common ones, adenocarcinomas and squamous carcinomas [2-4]. Even within patients at the earliest stages of the disease, a significant number recur after therapeutic surgery and adjuvant chemotherapy, and ultimately die from their disease. * Correspondence: [email protected] 1 Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Madrid, Spain Full list of author information is available at the end of the article
Lung cancer cure rate remains disappointing, with fiveyear survival rates limited to 15-20% [1]. Understanding the molecular basis of lung cancer will enable the identification of high-risk populations for effective early detection, and prognostic and predictive markers of tumor behaviour. Lung cancer can be described as a molecular disease, driven by the multistep accumulation of genetic, epigeneti
Data Loading...
